Dialysis‐related practice patterns among hemodialysis patients with cancer

Hiroki Nishiwaki, Shingo Fukuma, Takeshi Hasegawa, Miho Kimachi, Tadao Akizawa, Shunichi FukuharaHealth Science Reports 2018 · DOI

TL;DR

As hemodialysis patients live longer, cancer is becoming a more common comorbidity. This study investigated whether doctors adjust dialysis-related care for patients with cancer. While most aspects of care remained similar, patients with recent cancer treatment received higher doses of erythropoiesis-stimulating agents (ESAs).

What Problem Does This Paper Address?

The increasing longevity of patients undergoing hemodialysis (HD) means that cancer is becoming a more prevalent co-occurring condition. This raises questions about how to best manage these complex patients. Specifically, it's unclear if physicians alter their standard dialysis practices – which encompass anemia management, mineral and bone metabolism, nutrition, and the dialysis treatment itself – when a patient also has cancer. This is particularly relevant for anemia management, as guidelines for cancer patients often caution against ESA use due to potential adverse effects on cancer progression, creating a potential conflict with standard HD anemia protocols. This study aims to clarify current practice patterns in Japan to inform future care improvements.

Methods

The researchers conducted a cross-sectional analysis using baseline data from the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS) phase 4, which collected data from 2009-2011. They evaluated 2153 HD patients, categorizing them into three groups based on cancer status: no cancer, cancer with recent treatment (defined as treatment within the year prior to baseline), and cancer without recent treatment.

The study assessed several key areas of dialysis-related practice:

  • Anemia Management: This included measuring hemoglobin (Hb) and ferritin levels, tracking the use and dosage of erythropoiesis-stimulating agents (ESAs) like epoetin, darbepoetin, and epoetin beta pegol, calculating the erythropoietin resistance index (ERI), and noting the use of intravenous iron and blood transfusions.
  • Mineral and Bone Metabolism Disorder (MBD) Management: This involved analyzing serum levels of phosphorus, calcium, and intact parathyroid hormone, as well as the use of phosphate binders, vitamin D receptor activators, and cinacalcet.
  • Nutritional Management: Assessed through serum albumin levels and normalized protein catabolic rate (nPCR).
  • Dialysis Treatment: Evaluated using indicators such as single pool Kt/V, dialysis session duration, blood flow rate, and intradialytic weight loss.

Statistical analyses included descriptive statistics, ANOVA, and chi-squared tests to compare groups. To account for the clustering effect of dialysis facilities, generalized estimating equations (GEE) were used. Analyses were adjusted for age and other comorbidities in "fully adjusted" models.

Datasets

The study utilized data from the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS) phase 4. This is an existing, large-scale observational study of hemodialysis patients in Japan. No new datasets were introduced.

Key Insights and Ideas

  • ESA Use is Higher in Cancer Patients: The most significant finding is the increased use of ESAs in HD patients with recent cancer treatment. This suggests physicians may be prioritizing maintaining target hemoglobin levels, potentially to avoid transfusions, even in the context of cancer.
  • No Major Differences in MBD, Nutrition, or Dialysis: Despite cancer being a complex condition, the study found no statistically significant differences in how MBD, nutritional status, or core dialysis treatment parameters were managed between cancer patients and those without cancer. This implies a general standardization of these aspects of care.
  • Physician Practices Aren't Heavily Modulated by Cancer Status (Except for ESA): The overall finding suggests that, for the most part, physicians are not significantly altering their dialysis-related practices based on a patient's cancer status, with the notable exception of ESA dosing.
  • Baseline Characteristics Differ: Patients with cancer were generally older and more likely to be female, which aligns with general epidemiological trends for cancer risk.

Key Results

  • ESA Dose: Patients with recent cancer treatment received a higher mean ESA dose, with a multivariable-adjusted mean difference of 5.4 x 10³ IU/L/month compared to patients without cancer.
  • Hemoglobin Levels: Hemoglobin levels were similar across all cancer status groups (mean around 10.2-10.4 g/dL).
  • Phosphorus and Calcium: Levels of phosphorus and calcium were also similar between groups.
  • Nutritional Status: Serum albumin and nPCR were comparable across all groups.
  • Dialysis Treatment: Indicators like Kt/V, dialysis time, blood flow rate, and intradialytic weight loss showed no significant differences between groups.
  • Patient Population: Out of 2153 HD patients, 84 (3.9%) had cancer without recent treatment, and 68 (3.2%) had cancer with recent treatment.

Limitations and Future Work

The authors acknowledge several limitations:

  • Facility-Based HD Only: The study only included patients in long-term facility-based HD, excluding peritoneal dialysis, home dialysis, and predialysis patients.
  • Japanese Population: The findings are specific to Japanese HD patients and may not be generalizable to other populations.
  • Lack of Cancer Activity Data: The study did not capture crucial details about cancer activity, such as whether it was active or in remission, cancer type, or stage. This limits the ability to understand the impact of active disease.
  • Small Cancer Cohort: The relatively small number of cancer patients (n=152) limited the power to perform detailed analyses, particularly regarding associations between practice patterns and clinical outcomes.
  • Physician/Facility Dependence: The evaluation of cancer presence relied on physician and facility reporting, which could introduce bias.
  • Nutritional Indicators: The study used serum albumin and nPCR, but other nutritional indicators might provide a more comprehensive picture.

Future work should focus on larger, multi-national studies with more detailed cancer information to better understand the nuances of managing HD patients with cancer. Further research is also needed to explore the rationale behind increased ESA use in this population and its potential impact.

Summary updated

Abstract

Abstract Rationale, aims, and objectives With the achievement of longevity in hemodialysis patients, the risk of comorbid cancer has begun to draw attention. In the present study, we examined dialysis‐related practice patterns and compared those patterns by cancer status. Methods Using data from the Japan Dialysis Outcomes and Practice Patterns Study phase 4, we evaluated 2153 hemodialysis patients. Baseline cancer status for patients was separated into 3 categories: no cancer, cancer with recent treatment, and cancer without recent treatment. We then assessed variations among hemodialysis patients in dialysis‐related practice patterns, including anemia management, management of mineral and bone metabolism disorder, nutritional management, and dialysis treatment, by cancer status. Results We observed both similarities and differences in dialysis‐related practice patterns among hemodialysis patients, by cancer status. Hemoglobin levels were largely similar for all cancer statuses, although erythropoiesis stimulating agents dose tended to be higher in hemodialysis patients with recent cancer treatment (multivariable adjusted mean difference of erythropoiesis stimulating agents dose: 5.4 × 10 3 IU/L/month) than in those without cancer. Phosphorus and calcium levels were also similar. Nutrition statuses were similar among cancer statuses, as were dialysis therapies. These results suggested that physicians do not modulate their dialysis‐related practices based on whether or not a hemodialysis patient has cancer. Conclusion Among long‐term facility‐based hemodialysis patients with cancer, we detected no statistically significant differences to suggest that cancer status affects hemodialysis practice regarding mineral and bone disorder management, nutritional management, and dialysis treatment. Facility‐based hemodialysis patients with recent cancer treatment, however, receive a higher dose of erythropoietin‐stimulating agent than those without cancer.
BibTeX
@inproceedings{nishiwaki2018dialysisrelated,
  author = {Hiroki Nishiwaki and Shingo Fukuma and Takeshi Hasegawa and Miho Kimachi and Tadao Akizawa and Shunichi Fukuhara},
  title = {{Dialysis‐related practice patterns among hemodialysis patients with cancer}},
  booktitle = {Health Science Reports},
  year = {2018},
  doi = {10.1002/hsr2.46},
}
Figure